Overall, despite the high costs per treatment of these medicines (Table 1 ), their impact on the total INHS expenditure in 2023 (26.3 Bln €) is 4.6‰ and accounts for 7.4‰ when compared with the expenditure for medications directly purchased by health facilities (16.4 Bln€, Table 5 ). The expenditure for ATMPs is driven by CAR-T ex-vivo gene therapies (106.7 Mln € in 2023) with an increasing trend, while all other AMTPs generated a lower expenditure (14.7 Mln€ in 2023), in decline compared with 2021 and 2022 (Tab .5 ).
← all excerpts
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
1
—
—